Molecular Pathways and Mechanisms of BRAF in Cancer Therapy

Poulikos I. Poulikakos, Ryan J. Sullivan, Rona Yaeger

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


With the identification of activating mutations in BRAF across a wide variety of malignancies, substantial effort was placed in designing safe and effective therapeutic strategies to target BRAF. These efforts have led to the development and regulatory approval of three BRAF inhibitors as well as five combinations of a BRAF inhibitor plus an additional agent(s) to manage cancer such as melanoma, non–small cell lung cancer, anaplastic thyroid cancer, and colorectal cancer. To date, each regimen is effective only in patients with tumors harboring BRAFV600 mutations and the duration of benefit is often short-lived. Further limitations preventing optimal management of BRAF-mutant malignancies are that treatments of non-V600 BRAF mutations have been less profound and combination therapy is likely necessary to overcome resistance mechanisms, but multi-drug regimens are often too toxic. With the emergence of a deeper understanding of how BRAF mutations signal through the RAS/MAPK pathway, newer RAF inhibitors are being developed that may be more effective and potentially safer and more rational combination therapies are being tested in the clinic. In this review, we identify the mechanics of RAF signaling through the RAS/MAPK pathway, present existing data on single-agent and combination RAF targeting efforts, describe emerging combinations, summarize the toxicity of the various agents in clinical testing, and speculate as to where the field may be headed.

Original languageEnglish
Pages (from-to)4618-4628
Number of pages11
JournalClinical Cancer Research
Issue number21
StatePublished - 1 Nov 2022


Dive into the research topics of 'Molecular Pathways and Mechanisms of BRAF in Cancer Therapy'. Together they form a unique fingerprint.

Cite this